» Articles » PMID: 34666222

Molecular Profiling of Osteosarcoma in Children and Adolescents from Different Age Groups Using a Next-generation Sequencing Panel

Overview
Journal Cancer Genet
Publisher Elsevier
Specialty Oncology
Date 2021 Oct 19
PMID 34666222
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OS) is a malignant bone tumor, with a peak of incidence in the second decade of life and possibly associated with the presence of germline mutations. Besides, clinicians have pointed to a second, rarer group of patients that develops OS before 10 years old. Here we access, through next-generation sequencing (NGS) strategy, the genetic alterations present in OS and blood samples from patients diagnosed before and during the second decade of life. A custom NGS panel, designed for the main alterations described in childhood and adolescence neoplasms, named Oncomine Childhood Cancer Research Assay (OCCRA©), was used. Of all 84 OS samples investigated, 42 (50%) presented some somatic variant, with TP53, MYC, CDK4, RB1 and PDGFRA genes harboring the most observed genetic variants. MYC CNVs were more frequent in tumors from patients diagnosed before 10 years old (X= 5.18, p = 0.023). Additionally, patients diagnosed during the second decade of life presented a higher percentage of somatic and germline variants. Germline variants in TP53 and RB1 were found in 5 of the 11 (45.5%) patients analyzed. Clinical variables and tumor histopathological characteristics were also collected and correlated with our molecular findings.

Citing Articles

Genetic profiling of osteosarcoma in an adolescent using a next‑generation sequencing panel and Sanger sequencing: A case report and review of the literature.

Chantre-Justino M, Silvestre R, De Castro T, Luz E, Pinheiro R, Caruso A Biomed Rep. 2025; 22(3):42.

PMID: 39810900 PMC: 11729137. DOI: 10.3892/br.2025.1920.


Whole-Exome Analysis and Osteosarcoma: A Game Still Open.

Chiappetta C, Della Rocca C, Di Cristofano C Int J Mol Sci. 2025; 25(24.

PMID: 39769419 PMC: 11728052. DOI: 10.3390/ijms252413657.


A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors.

Goto H, Ohtsu T, Ito M, Sagisaka M, Naruto T, Nagai J Hum Cell. 2023; 36(6):2152-2161.

PMID: 37707773 DOI: 10.1007/s13577-023-00982-8.


Self-Renewal and Pluripotency in Osteosarcoma Stem Cells' Chemoresistance: Notch, Hedgehog, and Wnt/β-Catenin Interplay with Embryonic Markers.

Martins-Neves S, Sampaio-Ribeiro G, Gomes C Int J Mol Sci. 2023; 24(9).

PMID: 37176108 PMC: 10179672. DOI: 10.3390/ijms24098401.


Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.